Modeling of miRNA and Drug Action in the EGFR Signaling Pathway by Li, Jian et al.
Modeling of miRNA and Drug Action in the EGFR
Signaling Pathway
Jian Li*, Vikash Pandey, Thomas Kessler, Hans Lehrach, Christoph Wierling
Department Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany
Abstract
MicroRNAs have gained significant interest due to their widespread occurrence and diverse functions as regulatory
molecules, which are essential for cell division, growth, development and apoptosis in eukaryotes. The epidermal growth
factor receptor (EGFR) signaling pathway is one of the best investigated cellular signaling pathways regulating important
cellular processes and its deregulation is associated with severe diseases, such as cancer. In this study, we introduce a
systems biological model of the EGFR signaling pathway integrating validated miRNA-target information according to
diverse studies, in order to demonstrate essential roles of miRNA within this pathway. The model consists of 1241 reactions
and contains 241 miRNAs. We analyze the impact of 100 specific miRNA inhibitors (anit-miRNAs) on this pathway and
propose that the embedded miRNA-network can help to identify new drug targets of the EGFR signaling pathway and
thereby support the development of new therapeutic strategies against cancer.
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Introduction
MicroRNAs (miRNAs) are evolutionary conserved, endoge-
nous, non-protein-coding, 18–22 nucleotide RNAs that exert
function to negatively regulate gene expression at the post-
transcriptional level in a sequence-specific manner [1–3]. miRNAs
play important roles in nearly all biological processes, such as
developmental timing, cell proliferation, apoptosis, stem cell
maintenance, differentiation, signaling pathways, and pathogene-
sis including carcinogenesis [4–9]. To date, the human genome is
predicted to encode approximately 1,000 miRNAs, equivalent to
about 3% of the total number of human genes [10]. miRNAs
negatively regulate target gene expression via complementary base
pairing between their 59 seed sequence and the target mRNA 39
untranslated region. The 59 ‘‘seed’’ region of the miRNA sequence
(bases two to eight) is essential in mRNA target recognition [11].
miRNAs that bind to a protein encoding mRNA with imperfect
complementarity repress the mRNA translation, whereas miRNAs
binding to the mRNA with perfect complementarity target it for
destruction [12]. The expression of approximately 30% of human
proteins appears to be regulated by miRNAs [13]. Due to the
relatively few complementary base pairs, the target spectrum of
miRNAs can be very promiscuous. Although we do not know the
precise number of targets of each miRNA, it is reasonable to
suggest that the number could be in the hundreds. This means that
a single miRNA can target multiple components of a single cellular
pathway, or components of multiple pathways and therefore exert
profound impact on cell biology [14]. This could put an individual
miRNA in the unique position to function as a signaling amplifier,
to convey signaling crosstalk between pathways or to confer
signaling robustness of signaling pathways.
Cancer is a consequence of disordered genome function. A key
challenge in cancer research is explaining how cancer cells acquire
the fate of uncontrolled cell growth, aggressive invasion and
destruction of adjacent tissue and at the same time ignore and
circumvent apoptosis [15]. One approach in tumor therapy is to
specifically manipulate deregulated intracellular signaling path-
ways and to reduce the aberrant signal produced by over-
expressed oncogenes or alternatively to forcefully increase the
expression of tumor-suppressor genes. A yet untested alternative
approach might involve the use of miRNA targeting drugs that
could benefit from the potential broad impact which a particular
miRNA might have on multiple components within the same
deregulated signaling pathway.
The EGFR signaling pathway is one of the most important
cellular signaling pathways, which regulates relevant cellular
processes, including proliferation, differentiation, and develop-
ment [16]. Up-regulation and/or over-expression of EGFR
signaling have been associated with cancer-related processes,
including uncontrolled cellular proliferation and autocrine stim-
ulation of tumors producing their own growth factors. EGFR also
appears to protect cancer cells from toxic actions of chemotherapy
and radiotherapy, rendering these treatment modalities less
effective [17–19]. EGFR over-expression is frequently found in
epithelial tumor entities such as gastric, colorectal, head-and-neck,
breast, and lung cancers and is associated with advanced disease
and poor clinical prognosis [20,21].
In this study, we constructed a systems biological model of the
EGFR signaling pathway including corresponding miRNA-target
information based on diverse published miRNA studies (Table S1).
We then conducted in silico analysis of the impact of miRNAs and
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demonstrating the impact of miRNA regulatory processes on the
behavior of this signaling pathway. Furthermore, we quantitatively
elucidate the therapeutic concept ‘‘One hit – multiple targets’’
suggested by Wurdinger and Costa [22] hoping to open a new
avenue for drug development in cancer research.
Results
1. Establishment of an integrated miRNA-EGFR signaling
pathway model
The miRNA-EGFR signaling model was constructed using the
new version of PyBioS, a web-based modeling and simulation
software [23,24] (http://pybios.molgen.mpg.de). The model is
based on molecular interactions and comprises 1241 reactions and
901 entities. The entities defined in the model are summarized in
Table 1. The miRNA information is derived from miRBase [25]
as well as extensive literature search. Among the implemented
components, there are 26 sets of genes, compiled from groups of
individual genes that have been assigned to similar biological
functions. For instance, we defined MEK as a set of genes that
includes the individual genes for MAP2K1 and MAP2K2, two
closely related mitogen activated protein kinases. Furthermore, we
implemented sets of miRNA genes whose mature miRNAs have
the same targets in our model. For example, mir-631, mir-608,
mir-604, mir-492, and mir-30a have the common targets
TARBP2, RNASEN, DICER1 and DGCR8 [26–28]. Therefore,
we defined a gene set entity, named mir-TRDD including these 5
miRNA genes. Similarly, there are mRNA sets, miRNA sets and
protein sets which are produced by mRNA-transcription, miRNA-
transcription and mRNA-translation processes, respectively.
During construction of the model, we emphasized the biological
sense, meaning that each protein entity is produced in the
compartment cytoplasm by a translation reaction of a respective
mRNA entity, which is generated in the compartment nucleus by
the transcription reaction of a gene entity (Fig. 1B). Each mRNA
and protein entity participate in their own decay reaction. We
assume that each gene has basal expression. Therefore, the
concentration of an mRNA entity depends on the concentration of
its gene entity and the kinetic parameters of the corresponding
mRNA transcription and decay reaction, the concentration of a
protein entity depends on the concentration of its corresponding
mRNA entity and the kinetic parameters of reactions, in which this
protein entity takes part. The reactions are summarized in Table 1.
Transcriptions include gene transcription and miRNA gene
transcription, where gene transcription is defined as a one step
process assuming that basal transcription is generated by constitu-
tive action of a single transcription factor. The miRNA gene
transcription simplifies two processes: (i) miRNA gene transcription
catalyzed by DNA-polymerase II or DNA-polymerase III; (ii)
cropping of the primary transcript (pri-miRNA) into a hairpin
intermediate (pre-miRNA) by the nuclear 650 kDa microprocessor
complex, comprising in humans of the RNase III DROSHA
(RNASEN) and the DiGeorge syndrome critical region gene 8
(DGCR8) (see Fig. 1C). The miRNA binding target reaction
simplifies two processes: (i)maturemiRNA incomplexwith DICER
and TARB binds to the Ago-complex and turns it into the RNA-
induced silencing complex (RISC); (ii) RISC recognizes the target
mRNA and binds to it (see Fig. 1C). Furthermore, we modeled
clusters of distinct reactions involved in specific functions, such as
EGFR, small GTPase signaling, MAPK cascade, phosphatidylino-
sitol signaling, and Ca
2+ signaling. Fig. 1A depicts the general
overview of the EGFR signaling pathway of our model. The
detailed model information is available under http://www.molgen.
mpg.de/,sysbio/models/EGF_miRNA_model.html in the form
of Systems Biology Markup Language (SBML) [29].
2. Analysis of predictive ability of the model
After establishing the miRNA-EGF signaling model we set out to
validate its predictive value. Based on the simulation, we attempt to
predict the dynamics of the underlying biological system so that the
validity of the assumption can be tested. Therefore, the in silico
prediction should be first compared with the experiment. If any
inconsistency occurs at this stage, it indicates that the model
representation is incomplete or not good enough. If the model could
pass the initial validation, it can then be used to make predictions to
be tested by experiments, as well as to explore many interesting
questions that are not amenable to experimental inquiry. Hence, we
compared the predictive results generated by our model with
experimental data obtained in cell culture experiments. In a recent
study, Avraham et al [30] investigated the impact of 23 miRNAs on
the EGFR signaling pathway and used expression of multiple
immediate early genes (IEGs) in EGF treated MCF10A cells as a
transcriptional readout. In these cells, the authors individually over-
expressed 23 miRNAs and then measured the concentration of
IEGs mRNAs (Fig. 2A). We tested how well our model can reflect
the observations of Avraham’s study. Therefore, using Petri net
simulations of our model (see Material and Methods), we simulated
the effects of individual miRNA over-expression testing the same
miRNAs that were analyzed in the aforementioned study (Fig. 2B).
Notably, the model construction was performed independently
from the Avraham’s study, and we did not use any data from this
study to feed into our model. The visual comparison of both results
shows that our in silico simulation result is in good accordance with
the in vitro response of MCF10A cells to miRNA over-expression
(Fig. 2A,B). Therefore, the information on miRNA-target relation-
ships we obtained by literature mining to build the model proves
sufficient to qualitatively recapitulate the IEG transcriptional
response to a cells miRNA expression status in the context of an
activated EGFR pathway.
3. Simulation of putatively oncogenic properties of mir-
192
Next we wanted to examine the inhibitory effect of a given
miRNA on its putative targets within the EGFR signaling cascade.
Table 1. Summary of model components/reactions.
Component Number Reaction Number
gene 183 transcription 179
mRNA 78 translation 75
protein 133 decay 218
miRNA 241 complex-formation 115
compound 35 translocation 133
complex 131 phosphorylation 49
pseudo-object 100 dephosphorylation 40
activation 10
miRNA-binding 417
other types 5
Sum: 901 Sum: 1241
Compound is metabolite; complex includes protein-protein complex, protein-
gene-complex, mRNA-miRNA complex; pseudo-object includes protein
inhibitor and miRNA inhibitor.
doi:10.1371/journal.pone.0030140.t001
miRNA Modeling
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30140Figure 1. Overview of the model. A: The model of the EGFR signaling pathway contains 4 sub-pathways: MAPK pathway, PI3K-AKT pathway, Ca
2+
signaling pathway, PAK signaling pathway. B, C are parts of the model network visualized by PyBioS. B: The mRNA BAD-1 is produced by the
transcription reaction (1) of gene BAD and also takes part in decay reaction (2) and translation-reaction (3), which produces the protein BAD-1
(cytoplasm). The protein BAD-1 takes part in further three reactions that are the decay-reaction (4), phosphorylation reaction (5) and
dephosphorylation reaction (6). The phosphorylated protein P-AKT (plasma membrane) catalyzes the phosphorylation reaction, in which protein
BAD-1 is phosphorylated into P-BAD-1. Afterwards, the protein P-BAD-1 is then dephosphorylated; C: shows a simplified miRNA biogenesis, target
recognition and competitive anti-miRNA effect. (1) miRNA-gene transcription; (2) miRNA translocation (from nucleus into cytoplasm); (3) miRNA-
binding-target reaction; (4) miRNA binds to the miRNA inhibitor.
doi:10.1371/journal.pone.0030140.g001
miRNA Modeling
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regulates the expression of the genes MDM2 [31], EGFR [32],
PIK3CA [32], TP53 [31,33], PTEN [34], and CDKN1 [31]. We
therefore chose to test the impact of mir-192 levels on the EGFR
signaling response and performed simulations by varying mir-192
concentrations between 0 and 10,000 nM. We used this
concentration range as expression of an individual miRNA is
considered to vary widely in copy number per cell, with a few
tissue-specific species up to more than 10,000 copies per cell
(.2,000 nM) [35]. In these simulation experiments, expression of
other miRNAs was omitted to examine the effect of individual
miRNA regulation. Furthermore, the number of copies of an
individual mRNA present in a single cell is considered to vary over
four orders of magnitude (1 to .1,000 copies that is equivalent to
0.001 to 10 nM), with most mRNA species present in ,100 copies
and a few exceeding 1,000 copies [36]. Setting the concentration
of ligand protein EGF to 1 nM should realistically provide a long
and strong enough signal for its transduction through the entire
signaling pathway during the course of simulation. Some
compounds such as ATP and ADP were fixed to 1 nM, as well.
Thereby, it is ensured that signal transduction will not halt only
because of shortage of certain metabolites. The initial concentra-
tions of other entities including mRNAs, miRNAs, proteins,
complexes, etc. were set to 0 nM, which ensured the entire
signaling pathway would only be affected by the EGF signal
during simulation.
Modeling mir-192 over-expression using these experimental
conditions reveals that the concentrations of mir-192 target proteins
TP53, PTEN, MDM2 and CDKN1, are inversely correlated with
the mir-192 gene expression levels (Fig. 3A). Interestingly,
upregulated mir-192 gene expression is often seen in cancers [33],
and based on our modeling results we suggest that mir-192 over-
expression might confer a proliferative advantage of cancer cells by
simultaneous suppression of the proteins TP53, PTEN, MDM2 and
CDKN1. Notably, among the 241 miRNAs in our model, 44
miRNAs target TP53, 57 miRNAs target PTEN, and 10 target
MDM2 and mir-192 is one of few miRNAs in our model that
simultaneously target these 3 tumor suppressor proteins.
There is evidence that miRNA expression levels are correlated
with the development of various human cancers suggesting that
deregulated miRNAs might function as classical tumor suppressors
and oncogenes [5,37]. For example, mir-15a, mir-16 and let-7
have been found to be down-regulated in different types of cancer,
suggesting that they can act as tumor suppressor genes [5]. The
simulation result (Fig. 3A) indicates that mir-192 might function as
an Oncomir by repressing the expression of several tumor
Figure 2. Comparison of model predictions with experimental results. A: Experimental results of relative concentration changes of target
mRNAs according to individual miRNA over-expression experiments from the Avraham’s study [30] (Reprinted with permission from AAAS); B: in silico
prediction result of relative concentration changes of target-mRNAs according to each miRNA over-expression in the EGFR model. Both heatmaps
show very similar qualitative results (protein down-regulation), the only discrepancies are for miR-155 and miR-498. mRNAs with low concentration
changes (log2-ratio,0.001) are ignored and shown in ‘white’.
doi:10.1371/journal.pone.0030140.g002
miRNA Modeling
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important role of miRNAs within signaling cascades [2]. Since
the expression of the EGFR protein is down-regulated by
increasing mir-192 gene expression (Fig. 3A), the expression of
most downstream proteins within the EGFR signaling pathway
decreases (Fig. 3B) which illustrates the impact of a given miRNA
on a signaling pathway by directly targeting its receptor protein.
These results suggest that the oncogenic function of mir-192 might
be partially compensated by reduced EGF signaling activity due to
reduced EGFR protein levels. However, constitutive activating
mutations in signaling components downstream of EGFR, like
NRAS(Q61L) or BRAF(V600E), are common in cancer cells [38].
These mutations in combination with mir-192 over-expression
could probably circumvent the effect of negative regulation of
EGFR by mir-192 while retaining the putative mir-192 Oncomir
effect via TP53, PTEN, MDM2 and CDKN1. Furthermore, it is
noteworthy that there are 36 miRNAs in our model that target the
EGFR mRNA (Table S2). It will certainly be interesting to analyze
expression of these miRNAs in different cancer types with respect
to the mutational status of the individual cancer case.
4. Simulation of a mir-181 dependent EGFR signaling
threshold
AKT/PKB, apart from the MEK/ERK branch, is another
important kinase branch activated downstream of mitogen-
activated PI3K: EGFR+EGFRPI3KRPIP3RPDPK1RAKT
Rtarget proteins. According to previous studies, mir-181c targets
AKT [39] and MYC [40]. Next, we were interested in how the
EGFR signaling threshold (the minimal concentration of EGFR
receptor protein for activating downstream proteins by constitutive
input of the EGF signal) can be affected by mir-181c. Therefore,
we set the initial condition of mir-181c gene expression level to
1 nM and the concentration of EGF fixed to 1 nM. During the
simulation, the gene expression level of EGFR increases from
0.1 pM to 10 nM (Fig. 3C). At a threshold of 10 pM of EGFR,
EGF can activate the downstream signaling proteins as judged by
increasing concentrations of the chosen readout model compo-
nents. In a second simulation, we simulated knock down of mir-
181c by setting its gene expression level to zero, while all other
conditions remained identical (Fig. 3D). In the absence of mir-
181c, the threshold of the EGFR signaling activation is lowered to
Figure 3. Modeling of mir-192 and mir-181c effects on the EGFR signaling pathway. A: Increased expression of mir-192 gene corresponds
with a reduced level of targets’ protein expression; B: Concentrations of EGFR downstream activated proteins are inversely correlated with the mir-
192 gene expression level; C: simulation result with fixed mir-181c gene expression level (1 nM), whereas all other 240 miRNA genes are not
expressed. All 13 AKT-dependent proteins can only be activated after the concentration of EGFR protein is getting higher than 10 pM. This activation
threshold is due to the presence of mir-181c. D: represents another simulation result without the presence of mir-181c, additionally all other 240
miRNAs were not expressed, as well. At this condition, the activation threshold of these proteins is at 0.001 pM. By comparing these two results
(C, D), one can understand that mir-181c raises the activation threshold of the EGFR signaling pathway significantly.
doi:10.1371/journal.pone.0030140.g003
miRNA Modeling
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potentially contribute to fine tuning of the EGFR signaling
threshold in a range from 0.001 pM to 10 pM of the EGFR
protein under these simulation conditions. Our results therefore
exemplify a crucial role that miRNAs might play in signaling
cascades by dampening positive mediators, restricting the signal to
an appropriate competence zone. Hence, miRNAs targeting
important components of a signaling pathway might be able to
regulate their target to achieve optimal signaling efficacy and limit
undesired signaling fluctuations, which is essential for genes
expressed at low levels, because stochastic changes in the
activation of their promoter are more genetically prominent [41].
5. Evaluation of the ‘‘One hit – Multiple Targets’’ concept
using miRNA modeling
Evidence from various studies indicates that normal miRNA
expression is important for proper development and differentiation
in a tissue and cell-type specific manner [22]. Deregulation of
miRNA expression is therefore a common feature of many types of
cancer [42]. However, one important question remains un-
touched: whether the miRNAs are differentially expressed as a
consequence of the pathologic cell state, or whether the particular
cancer or disease is a direct cause of the deregulated expression of
miRNAs. However, the therapeutic concept ‘‘One Hit – Multiple
Targets’’ could provide a solution to this problem.
The idea behind this concept from Wurdinger’s study [22] is to
normalize or to correct a deregulated miRNA expression, which
then directly or indirectly affects its protein-coding mRNA targets.
Some of these targets may be encoded by oncogenes and tumor
suppressor genes and the defects in those mRNA expression levels
could be immediately reverted to normal state by normalization of
deregulated miRNA expression. This restoration of the deregu-
lated post-transcriptional control could have immense therapeutic
benefit. In the following, we perform in silico simulation to
quantitatively elucidate the effect of two miRNA inhibitors on the
EGFR signaling pathway: anti-mir-489 and anti-mir-34a. In
general, anti-miRNAs could be designed in form of antagomirs,
which are anti-miRNA oligonucleotides (AMOs) conjugating with
cholesterol [43]; alternatively, they can be designed as locked-
nucleic-acid anti-sense oligonucleotides (LNAs) [44,45]. In both
cases, specific anti-miRNAs bind to their corresponding mature
endogenous miRNA according to sequence complementarity, thus
effectively blocking miRNA inhibitory function. The anti-mir-489
specifically antagonizes the inhibition effect of mir-489, which
targets CDKN1, PIK3CA, TP53 and AKT [46], and anti-mir-34a
antagonizes the inhibition effect of mir-34a, which targets MTOR,
ERK, MDM2, PIK3R1, EGFR, RPS6KA5, CAMK, TP53,
PTEN, PKC, PDPK1, MYC, CDKN1 and ELK1 [47–54]. In
order to study the potential anti-miRNA effects in silico, we carried
out two simulation processes and separately investigated both
inhibitor effects and additionally the downstream effect on the
EGFR signaling pathway. Therefore we performed in silico
experiments with different concentrations of anti-mir-489 (Fig. 4A
and B). The heatmap of Fig. 4A shows the change in concentration
of mir-489 target proteins, whereas Fig. 4B depicts the change of
concentration of the downstream proteins in the EGFR signaling
pathway. The results show a correlation between the concentrations
of these four target proteins and the amount of anti-mir-489, which
indicates that the miRNA-489 inhibitory effect is effectively
abolished by this anti-miRNA. Actually, anti-mir-489 exerts its
inhibitor effect not only on these four target proteins of mir-489, but
also indirectly influences downstream proteins of the EGFR
signaling pathway through those target proteins (Fig. 4B). This
reflects the ‘‘One Hit – Multiple Targets’’ effect of anti-miRNA.
According to the simulation results (Fig. 4.), we expect a functional
relevant concentration range of an anti-miRNA drug to be in
between 10 nM and 100 nM, which suggests a suitable range to test
the potential drug effect in, for example, cultured cancer cell lines.
Figure 4. Modeling of anti-mir-489 and anti-mir-34a effects on the EGFR signaling pathway. Heatmaps A and B are the results of anti-
mir-489 simulations. C and D are the results of anti-mir-34a simulations. The first experiment within each heatmap (from bottom to top) is the
‘control’ state; the miRNA effect and anti-miRNA effect of the different experiments is always compared versus the ‘control’ state. A: Quantitative
changes of mir-489 direct target-proteins due to different amounts of anti-mir-489 per experiment. The inhibition effects of mir-489 is inversely
correlated with the anti-mir-489 concentration. B: Quantitative changes of the EGFR downstream activated proteins according to different amounts
of anti-mir-489 per experiment. The concentrations of many downstream activated proteins of the EGFR signaling pathway correlate with the
concentration of anti-mir-489. C: Quantitative changes of mir-34a direct target-proteins due to different amounts of anti-mir-34a per experiment. The
inhibition effects of mir-34a inversely correlate with the anti-mir-34a concentration. D: Quantitative changes of the EGFR downstream activated
proteins according to different amounts of anti-mir-34a per experiment. The concentrations of many downstream activated proteins correlate with
the anti-mir-34a concentration.
doi:10.1371/journal.pone.0030140.g004
miRNA Modeling
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concentrations of anti-mir-34a (Fig. 4C and 4D). The anti-mir-
34a inhibits mir-34a in the same way as anti-mir-489 inhibits mir-
489. The common phenomenon of the application of both anti-
miRNAs is that not only the expression levels of target proteins
(Fig. 4 A and C), but also the indirect target proteins (Fig. 4B and
D) can be reverted to the normal expression levels (the ‘‘control’’
state), by increasing anti-miRNA concentrations to a certain level
(10 nM). Both results reveal the crucial role of ‘‘One Hit –
Multiple Targets’’ in the signaling cascade. ‘Correcting’ miRNA
inhibitory effect can lead to normalizing the expression levels of its
numerous target proteins, some of which may function as onco-
proteins and tumor-suppressor proteins. This might result in
recovery of the normal phenotype of a cell from a disease state to a
normal state. However, there are also differences between the
effect of mir-34a and anti-mir-489, for instance, there are five
proteins (Active-NF-kB, P-CREB1, P-MYC, P-ELK1 and P-
AFT1), which do not change at all due to anit-mir-489 (Fig. 4B),
while all the downstream proteins were affected by mir-34a and its
anti-mir (Fig. 4D). It seems that anti-mir-34a has more profound
effects on this signaling pathway than anti-mir-489 does. However,
this could be due to the fact that mir-34a targets 14 proteins in the
EGFR signaling pathway, while mir-489 targets only four.
Next, we assessed the potential effects of 100 different anti-
miRNAs individuallyand selected 19 important downstream proteins
of the EGFR signaling pathway as readout components of
effectiveness of anti-miRNAs. An anti-mir-combination effect was
not considered. Using this in silico simulation approach, we found
clear differences of anti-mir effects on this signaling pathway. For
instance, anti-mir-155 has considerable influence on the activation of
many downstream proteins and is thereforeconsidered as an effective
anti-miRNA (Fig. 5A), whereas anti-mir-663 exerts almost no effect
on this pathway and is therefore regarded as a non-effective or less
effective anti-miRNA for this signaling pathway (Fig. 5B). Further-
more, based on this simulation data, we investigated the concentra-
tion changes of all model components due to the effect of each anti-
miRNA, applied a statistical t-test and calculated the P-value of each
anti-miRNA according to its effect on the entire signaling pathway
(see Materials and methods). Table 2 lists the top 15 anti-miRNAs
with most significant P-values (P-value,0.05). Thus, we believe that
those anti-miRNAs should be suitable as potential candidates for
cancer treatment. However, those anti-miRNAs need to be tested
a n dv e r i f i e db yin vitro and in vivo experiments.
Afterwards, we investigated the corresponding 15 miRNAs with
their target information and another 15 miRNAs whose anti-
miRNAs have almost no effect on the EGFR signaling pathway
(Fig.6A and B). Wecounted the numberoftargets ofthosemiRNAs
individually according to the information in Table S1. As expected,
we found that an anti-miRNA that antagonizes a miRNA with
more targets, can exert a greater impact on the signaling pathway.
In contrast, an anti-miRNA appears less effective, if the anti-
miRNAantagonizesamiRNAwithveryfewtargets.However,anti-
mir-181c, anti-mir-214 and anti-mir-200a can also exert consider-
able impact on this signaling pathway during simulation, although
thenumberofdirecttargetsofthesethreemiRNAsarelow(Fig.6A).
The reason for this could be that they target key components of the
EGFR signaling pathway, for instance, mir-181c targets AKT and
MYC (see above). This phenomenon helps to understand the
principle of ‘‘One Hit – Multiple Targets’’ approach.
Discussion
Since the discovery of miRNAs in 1998, the function of those
molecules in oncogenesis and cancer progression has been a major
subject of intense investigation. One way to conceptualize the roles
of the miRNAs is in the context of an integrated network emerging
from summation of the interactions of miRNAs and their targets.
In this study, we constructed a systems biological miRNA-model of
the EGFR signaling pathway using the software PyBioS. The
miRNA-target information is based on diverse studies (Table S1).
The absorption of an extracellular signal, in this case EGF ligand,
must not induce some specific cellular instructions. Actually, it is
the cell that interprets the signal according to its history and actual
environment. In this case, our model can be considered as a virtual
cell functioning only with the EGFR signaling pathway and the
initial conditions of the model can be viewed as the virtual
environment in which this virtual cell is living. We showed the
predictive ability of our model by comparing the in silico simulation
data with the experimental results from the study of Avraham et al
[29] and reached high accuracy. Therefore, we conclude that our
model should be able to predict cellular responses to altered
miRNA levels. Based on this model, we conducted quantitative
miRNA and anti-miRNA in silico analysis of the effects of miRNA
expression levels and the resulting alterations evoked by miRNA
inhibitors. We demonstrated that some miRNAs could play an
essential role in the EGF triggered signaling cascade and some
anti-miRNAs might have considerable effect on this pathway. For
instance, by increasing the expression level of mir-192 in our
model, we showed that not only the expression of its direct target
proteins were reduced, but also many downstream proteins were
affected indirectly, indicating that altered miRNA expression level
might have a direct and indirect impact on the EGFR signaling
pathway. Furthermore, we demonstrated that mir-181c is able to
raise the activation threshold of the EGFR signaling pathway,
which potentially optimizes the signal efficacy, and limits
undesired signaling fluctuations. We demonstrated that by
administration of a proper amount of anti-mir-34a and anti-mir-
489 in silico, the direct and indirect target proteins of the EGFR
signaling pathway could be reverted to a normal state, which
indicates that a phenotype of a cell from a disease state could be
reverted to a normal state by anti-miRNAs inhibition and
elucidates the therapeutic benefit of anti-miRNA drugs.
Moreover, we studied 100 different anti-miRNAs by investigat-
ing their effect on the downstream proteins of the EGFR signaling
pathway. As expected, our simulation results indicate that the
more targets a miRNA has in the EGFR signaling pathway, the
more likely is the corresponding anti-miRNA to exert considerable
effect on this pathway. However, we show that targeting key
components of the signaling pathway is more important and
effective. Based on the simulation data, we propose a top 15 list of
anti-miRNAs (p,0.05) with most significant impact on the EGFR
signaling pathway (Table 2), and suggest that those anti-miRNAs
could be potential test candidates for follow-up studies assessing
the impact of distinct miRNA inhibitors on EGFR pathway
activation in cancer derived cell lines or other suitable model
systems. One particularly interesting candidate could be anti-mir-
21. mir-21 has been implicated as an oncogene in different types of
cancers such as breast-, colon-, cervical-cancer and glioblastoma
and a higher level of mir-21 is often correlated with poorer survival
of patients [55], [56,57]. Based on our simulation results, the
inhibition of mir-21 leads to a significant up-regulation of pro-
apoptotic proteins such as CASP9, BAD, TP53. This is in
agreement with the study conducted by Chan et al [55], where
mir-21 has been shown to be an anti-apoptotic factor. Moreover,
the inhibition of mir-21 also leads to the up-regulation of CDKN1,
a tumor-suppressor that regulates the cell cycle progress [58,59].
The down-regulation of CDKN1 supports the oncogenic activity
of mir-21. In 2010, an independent study of Mei et al [60]
miRNA Modeling
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30140Figure 5. Modeling the individual effect of 100 anti-miRNAs. A and B: Each anti-miRNA is activated when the corresponding miRNA is over-
expressed individually (an anti-mir-combination effect is omitted). Each row in this heatmap represents the predicted anti-miRNA effect and the more
columns in the same row appears red or orange, the stronger is the predicted effect that this particular miRNA inhibitor can exert on the EGFR
signaling pathway. In this manner, we can examine the impact of each anti-miRNA on this signaling pathway.
doi:10.1371/journal.pone.0030140.g005
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peutic effect in breast carcinoma cells. Based on our simulation
results, we suggest that an anti-mir-21 (p-value: 1.90e-06) could be
an effective anti-cancer drug also for other types of cancer with
elevated EGFR signaling. Furthermore, according to our simula-
tion results, the application of anti-mir-335 can lead to the up-
regulation of many essential tumor suppressors such as CDKN1,
TP53, CASP9 and TSC2. In 2011, an independent study of Shu
et al [61] elucidated the oncogenic potential of mir-335 and
validated that the inhibition of mir-335 can inhibit the growth and
invasion of malignant astrocytoma cells. Therefore, we suggest
that anti-mir-335 (p-value: 1.85e-03) might be an effective anti-
cancer drug for other types of cancer, similar to the potential
benefits of an anti-mir-21. Similarly, the anti-mir-221 (p-value:
3.64e-04) and anti-mir-222 (p-value: 1.81e-03) exerted significant
impact on model components during in silico simulation. In 2011,
Stinson et al [62] substantiated that specific miRNA such as mir-
221 and mir-222 can promote transformation to more aggressive
cancer phenotype with poor diagnosis. Hence, the therapeutic
value of the application of both anti-mir-221/222 should not be
underestimated. We therefore conclude that our modeling results
with respect to the impact of miRNAs on the EGFR pathway are
in good accordance with published data of some of the miRNAs
that are relevant in cancer treatment. The other eleven anti-
miRNAs we identified to have the greatest impact on the EGFR
signaling pathway (Table 2) have not been tested for their anti-
oncogenic properties in vivo and we suggest that they should be of
importance for in vitro or in vivo follow-up studies.
Surprisingly, we noticed that among the 241 miRNAs of our
model, 130 miRNAs target DICER, and 45 miRNAs target
RNASEN (Table S2), whose protein products process pre-miRNA
into mature, functional miRNA thereby playing an essential role in
the miRNA-biogenesis process. This raises the interesting question
whether those 175 miRNAs regulate the overall mature miRNAs
level through targeting the mRNAs of both genes. William et al [63]
discovered that in some types of tumor, such as ovarian cancer, a
lower DICER expression wassignificantly associated with advanced
tumor stage. DICER down-regulation has also been discovered in
various cancer types by other groups [64–66]. This DICER
misregulation could reflect a globally impaired expression of mature
miRNAs in human cancers [67,68].
One limitation of our current EGFR signaling model is that
ErbB2–4 are not taken into consideration and we analyze EGFR
(ErbB1) as a single and isolated cell surface receptor. The future
work could be adding the combination of homo- and hetero-
dimerization of these four ErbB family members. Furthermore,
our model assumes that each gene has basal expression and we
have not added specific transcription factors or expression data for
all transcription reactions. Similarly, for the phosphorylation
reactions, we have not considered the detailed information of the
phosphorylation sites of proteins. Despite of those flaws, our model
could effectively be employed for estimating miRNAs inhibition
effect.
Recently, RNAi based methodologies have been widely used in
order to silence a single target gene, and have contributed to
advances in molecular biology [69,70]. However, various studies
using microarray based expression screens have indicated that in
pathological tissues there can be an imbalanced gene expression
pattern involving many genes [71,72], which can reduce the
usefulness of those RNAi technologies dramatically. In contrast,
the concept that one miRNA can manipulate several genes
involved in one or many signaling pathway seems to be very
promising and effective for cancer treatment. Furthermore, Iguchi
et al [57] pointed out that the therapeutic intervention of miRNA
Table 2. Top 15 anti-miRNAs.
anti-miRNA P-value
Anti-mir-21 1.90e-06
Anti-mir-155 4.54e-06
Anti-mir-221 3.64e-04
Anti-mir-17 1.44e-03
Anti-mir-489 1.78e-03
Anti-mir-222 1.81e-03
Anti-mir-335 1.85e-03
Anti-mir-126 1.86e-03
Anti-mir-100 3.50e-03
Anti-mir-181c 1.17e-02
Anti-mir-214 1.18e-02
Anti-mir-200a 1.19e-02
Anti-mir-34a 1.26e-02
Anti-let-7c 3.22e-02
Anti-mir-182 4.22e-02
P-value gives the significant level of concentration-differences of all model
components between the state of the applied specific anti-miRNA and control
state (inactivated anti-miRNA).
doi:10.1371/journal.pone.0030140.t002
Figure 6. Histogram of miRNA/target relationships. A: The top ranked 15 miRNAs of Table 2 correlated with the amount of their
corresponding targets in the EGFR signaling pathway (Table 1). B: The 15 miRNAs correlated with amount of their corresponding targets in EGFR
signaling pathway. The anti-miRNAs of these miRNAs have much less effect on this pathway (Fig. 5A and B).
doi:10.1371/journal.pone.0030140.g006
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conducted by Okamura et al [73] and Calin et al [74] explain the
passenger strand effect, meaning that the passenger strand of the
mature miRNA exerts an inhibitory effect and confers resistance
to miRNA regulation, respectively. These finding indicate that
cancerous cells are able to eliminate the therapeutic effect of a
miRNA. Therefore, we believe that a combined therapeutic
strategies might be needed to succeed in clinical application of
anti-miRNA drug.
Materials and Methods
1. Petri Net Extension
The simulation processes are based on the Petri net, which is a
graphical and mathematical modeling language developed in the
early 1960s by Carl Adam Petri [75]. The Petri nets approach has
subsequently been adapted and extended in many fields such as
systems biology. Furthermore, many extensions to Petri nets have
been developed for various modeling and simulation purposes
[76]. We implemented a Petri nets extension for the PyBioS
software [24], which includes the characteristics of hierarchical-,
hybrid- and timed-Petri nets. Therefore, it is particularly suitable
for the simulation of large-scale networks. In the following, we
explain the simulation process.
In our model network, places and transitions represent bio-
objects (gene, mRNA, miRNA, protein and compound) and
biochemical reaction, respectively (Fig. 7). Each place is marked
with a value representing the concentration of a model
component.
Formal definition of Petri nets [77]:
A Petri net is a 6-tuple, PN=(P, T, F, W, m, D)
where:
P={ p 1,p 2 ,…,p x}is a finite set of places (model
contains x bio-objects),
T={t 1,t 2 ,…,t y} is a finite set of transitions (model
contains y reactions),
F is subset of [( P x T ) U (T x P ) is a set of arcs]
W: FR{0, 1, 2, .. x } is a weight function,
m: PR{0, 1, 2, .. x } is the initial marking,
P >T=Ø (meaning that the sets P and T are disjointed),
D: mRPR{p1,p 2 ,…,p x} is the decay rate function of
each component.
During simulation in each time ste p ,e a c ht r a n s i t i o ni se v a l u a t e d
with transition speed as ‘activated’ or ‘not activated’. If an activated
transition can fit to a certain criteria, then it can fire, referring to
biological sense, this reaction can occur. The transition speed is
calculated by individual functions Fy(S, E, I) referring the corre-
sponding substrate S, enzyme E and Inhibitor I for each reaction y.
For instance, the speed of transition t1:
F m BAD ðÞ ,m ATP ðÞ ,mP {AKT ðÞ ðÞ ~
m BAD ðÞ
W BAD ðÞ
 
m ATP ðÞ
W ATP ðÞ
 
mP {AKT ðÞ
WP {AKT ðÞ
Figure 7. Transition fire of Petri Nets. An exemplary phosphorylation reaction of the Petri Nets. BAD-1 (p1), ATP (p2), P-BAD-1 (p3), ADP (p4) and
P-AKT (p5) are places and phosphorylation reaction (t1) is a transition. A: the concentrations of model components at time point 0 (before transition
fire); B: the concentrations of components in model at time point 1 (after transition fire).
doi:10.1371/journal.pone.0030140.g007
Table 3. Transition t1 at time point 0 (before firing).
Components Concentrations
BAD-1 1.0
ATP 2.0
P-AKT 3.0
P-BAD-1 0.0
ADP 0
doi:10.1371/journal.pone.0030140.t003
Table 4. Transition t1 at time point 1 (after firing).
Components Concentrations
BAD-1 0.95 – 0.09
ATP 1.95 – 0.18
P-AKT 2.95 – 0.27
P-BAD-1 0.05 – 0.05*0.09
ADP 0.05 – 0.05*0.09
doi:10.1371/journal.pone.0030140.t004
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places BAD, ATP and P-AKT; W(BAD), W(ATP) and W(P-AKT)
are the weights of the places.
If the following conditions hold true:
speed~F m BAD ðÞ ,m ATP ðÞ ,mP {AKT ðÞ ðÞ w0
^ m BAD ðÞ §speed ^ m ATP ðÞ §speed
the transition t1 fires in forward direction, meaning that this
phosphorylation reaction takes place.
If the following conditions hold true:
speed~F m BAD ðÞ ,m ATP ðÞ ,mP {AKT ðÞ ðÞ v0
^ m BAD ðÞ ƒspeed ^ m ATP ðÞ ƒspeed
the transition t1 fires in backward direction, meaning that the
dephosphorylation reaction takes place.
If one of the above two conditions is fulfilled, but the enzyme P-
AKT is present at low concentration, the reaction can take place.
However, its reaction flux will be low, too.
For example, at time point 0, initial concentrations of BAD-1,
ATP and P-AKT are 1.0, 2.0 and 3.0, and we assume that their
weight function values are
W BAD ðÞ ~5, W ATP ðÞ ~5, WP {AKT ðÞ ~5,
then the decay function values are
D BAD ðÞ ~m BAD ðÞ   0:09~0:09
D ATP ðÞ ~m ATP ðÞ   0:09~0:18
DP {AKT ðÞ ~mP {AKT ðÞ   0:09~0:27
and the speed is calculated by f1 :
speed~F m BAD ðÞ ,m ATP ðÞ ,mP {AKT ðÞ ðÞ ~0:05
Table 3, 4 show the concentration-changes of components of
reaction t1 from the time point 0 to time point 1.
It is noteworthy to mention that we take multiple time scales of
intracellular biochemical reactions into consideration. For proteins
and components, the decay takes place each time according to
their individual decay function D(m(proteins)*0.09) with 0.09 as
decay kinetic parameter; for ligand-receptor complex, the decay
takes place every 10 times according to their individual
D(m(ligand-receptor complex)*0.2) with 0.2 as decay kinetic
parameter. Currently, these different decay kinetic parameters
are based on empirical experience. All types of kinetic parameters
applied in Petri Nets simulation are summarized in Table 5.
2. Analysis of significant changes of model components
due to the effect of anti-miRNAs
Significance analysis of concentration changes of all model
components were performed using t-test [78]. Suppose the model
contains n components and CX symbolizes the simulated
concentration of one model component and for the state of the
application of anti-miRNA (e.g. anti-mir-21)
Vanti{mir~ C1, C2, C3 ,:::,Cn ½ 
where Cx is the concentration of one model component in the
current state, and for the corresponding control state (e.g. mir-21)
Vcontrol~ C0
1, C0
2, C0
3 ,:::,C0
n

where C9x is the concentration of one model component in the
control state the p-value is copmuted by the t-test:
P{value~t:test Vanti{mir,Vcontrol ðÞ
Supporting Information
Table S1 Reference list of miRNA-targets.
(TXT)
Table S2 Classification of miRNAs according to their targets.
(TXT)
Acknowledgments
We thank Dr. Dr. Michal-Ruth Schweiger for proofreading the
manuscript.
Author Contributions
Conceived and designed the experiments: JL HL CW. Performed the
experiments: JL. Analyzed the data: JL VP CW. Wrote the paper: JL VP
TK CW.
References
1. Cho WC (2007) OncomiRs: The discovery and progress of microRNAs in
cancers. Mol Cancer 6: 60.
2. Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in
cancer. Nat Rev Cancer 6: 259–269.
Table 5. The summary of kinetic parameters applied in the Petri nets simulation.
Reaction Type Kinetic Parameter Reaction Type Kinetic Parameter
Complex Formation 0.55 Translocation 0.8
Phosphorylation 0.35 Translocation (mRNA) 0.5
Dephosphorylation 0.01 Dephosphorylation(enzym) 0.15
Transcritpion 0.5 Inhibitory parameter 1.5
Decay 0.02 other parameter 0.35
doi:10.1371/journal.pone.0030140.t005
miRNA Modeling
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e301403. Voorhoeve PM, Agami R (2007) Classifying microRNAs in cancer: The good,
the bad and the ugly. Biochim Biophys Acta 1775: 274–282.
4. Bueno MJ, de Castro IP, Malumbres M (2008) Control of cell proliferation
pathways by microRNAs. Cell Cycle 7: 3143–3148.
5. Hwang HW, Mendell JT (2006) MicroRNAs in cell proliferation, cell death, and
tumorigenesis. Br J Cancer 94: 776–780.
6. Wang Y, Blelloch R (2009) Cell cycle regulation by microRNAs in embryonic
stem cells. Cancer Res 69: 4093–4096.
7. Zhang B, Pan X, Cobb GP, Anderson TA (2007a) MicroRNAs as oncogenes
and tumor suppressors. Dev Biol 302: 1–12.
8. Zhang BH, Wang QL, Pan XP (2007b) MicroRNAs and their regulatory roles in
animals and plants. J Cell Physiol 210: 279–289.
9. Zhang BH, Farwell MA (2008) A new emerging class of player for disease
diagnostics and gene therapy. J Cell Mol Med 12: 3–21.
10. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 116: 281–297.
11. Lytle RJ, Yario TA, Steitz JA (2007) Target mRNAs are repressed as efficiently
by microRNA-binding sites in the 59 UTR as in the 39 UTR. PNAS 104:
9667–9672.
12. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, et al.
(2010) Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21.
Cancer Cell 18: 282–293.
13. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by
adenosine, indicates that thousands of human genes are microRNA targets. Cell
120: 15–20.
14. Chiocca EA, Lawler SE (2010) The Many Functions of MicroRNAs in
Glioblastoma. World Neurosurgery 73(6): 598–60.
15. Hanahan D, Weinberg RA (2011) Hallmarks of Cancer: The Next Generation.
Cell 144(5): 646–74.
16. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, et al. (2008)
Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer
Cells by MicroRNA-7. J Biol Chem 284(9): 5731–41.
17. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:
355–365.
18. Chen X, Yeung TK, Wang Z (2000) Enhanced drug resistance in cells
coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res 277:
757–763.
19. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance.
J Pathol 205: 275–292.
20. Gross ME, Shazer RL, Agus DB (2004) Targeting the HER-kinase axis in
cancer. Semin Oncol 31: 9–20.
21. Yano S, Kondo K, Yamaguchi M, Richmond G, Hutchison M, et al. (2003)
Distribution and function of EGFR in human tissue and the effect of EGFR
tyrosine kinase inhibition. Anticancer Res 23: 3639–3650.
22. Wurdinger T, Costa F (2007) Molecular therapy in the microRNA era. The
Pharmacogenomics Journal 7: 297–304.
23. Wierling C, Herwig R, Lehrach H (2007) Resources, standards and tools for
systems biology. Briefings in Functional Genomics and Proteomics 6(3):
240–251.
24. Klipp E, Liebermeister W, Wierling C, Kowald A, Lehrach H, et al. (2009)
System Biology – A Textbook, 68–70. WILEY-VCH, Weinheim, Germany.
25. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ (2008) miRBase: tools for
microRNA genomics. NAR 34(Database Issue): D140–D144.
26. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, et al. (2006) The
colorectal microRNAome. Proc Natl Acad Sci U S A 103(10): 3687–92.
27. Clague J, Lippman SM, Yang H, Hildebrandt MA, Ye Y, et al. (2010) Genetic
variation in MicroRNA genes and risk of oral premalignant lesions. Mol
Carcinog 49(2): 183–9.
28. Ye Y, Wang KK, Gu J, Yang H, Lin J, et al. (2008) Genetic variations in
microRNA-related genes are novel susceptibility loci for esophageal cancer risk.
Cancer Prev Res(Phila) 1(6): 460–469.
29. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, et al. (2003) The systems
biology makeup language (SBML): a medium for representation and exchange of
biochemical network models. Bioinformatics 19(4): 524–531.
30. Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, et al. (2010) EGF
decreases the abundance of microRNAs that restrain oncogenic transcription
factors. Science Signaling 3(124).
31. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, et al. (2008) p53-
Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.
Cancer Res 68(24): 10094–104.
32. Yantiss RK, Goodarzi M, Zhou XK, Rennert H, Pirog EC, et al. (2009)
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.
Am J Surg Pathol 33(4): 572–82.
33. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, et al. (2008) Coordinated
regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and
miR-215. Cancer Res 68(24): 10105–12.
34. Kato M, Putta S, Wang M, Yuan H, Lanting L, et al. (2009) TGF-beta activates
Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN.
Nat Cell Biol 11(7): 881–9.
35. Liang Y, Ridzon D, Wong L, Chen C (2007) Characterization of microRNA
expression profiles in normal human tissues. BMC Genomics 8: 166.
36. Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, et al. (2010)
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of
miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol
220(1): 58–70.
37. Chen CZ (2005) MicroRNAs as oncogenes and tumor suppressors. N Engl J Med
353: 1768–1771.
38. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, et al. (2008) The
Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum
Genet 10: 11.
39. Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, et al. (2009)
The kinase Akt1 controls macrophage response to lipopolysaccharide by
regulating microRNAs. Immunity 31(2): 220–31.
40. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, et al. (2008) Mature miR-184
as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue.
Clin Cancer Res 14(9): 2588–92.
41. Raser J, Shea E (2010) Noise in Gene Expression: Origins, Consequences, and
Control. Science 309: 2010–2013.
42. Shi M, Liu D, Duan HJ, Shen BF, Guo N (2010) Metastasis-related miRNAs,
active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev
29(4): 785–799.
43. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, et al. (2005)
Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438: 685–689.
44. Orom UA, Kauppinen S, Lund AH (2006) LNA-modified oligonucleotides
mediate specific inhibition of microRNA function. Gene 372: 137–141.
45. Vester B, Wengel J (2004) LNA (locked nucleic acid): high-affinity targeting of
complementary RNA and DNA. Biochemistry 43: 13233–13241.
46. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008) MicroRNA-
221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.
J Biol Chem 283(44): 29897–903.
47. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, et al. (2010) miR-221
overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A
107(1): 264–9.
48. Li N, Fu H, Tie Y, Hu Z, Kong W, et al. (2009) miR-34a inhibits migration and
invasion by down-regulation of c-Met expression in human hepatocellular
carcinoma cells. Cancer Lett 275(1): 44–53.
49. Asslaber D, Pin ˇo ´n JD, Seyfried I, Desch P, Sto ¨cher M, et al. (2010) microRNA-
34a expression correlates with MDM2 SNP309 polymorphism and treatment-
free survival in chronic lymphocytic leukemia. Blood 115(21): 4191–7.
50. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, et al. (2008)
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-
regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.
Cancer Res 68(9): 3193–203.
51. Markey M, Berberich SJ (2008) Full-length hdmX transcripts decrease following
genotoxic stress. Oncogene 27(52): 6657–66.
52. Zenz T, Ha ¨be S, Denzel T, Mohr J, Winkler D, et al. (2009) Detailed analysis of
p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia
(CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53–p21
dysfunction, and miR34a in a prospective clinical trial. Blood 114(13): 2589–97.
53. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, et al. (2009) Evidence
for selective microRNAs and their effectors as common long-term targets for the
actions of mood stabilizers. Neuropsychopharmacology 34(6): 1395–405.
54. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, et al. (2010) p53-
independent upregulation of miR-34a during oncogene-induced senescence
represses MYC. Cell Death Differ 17(2): 236–45.
55. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic
factor in human glioblastoma cells. Cancer Res 65: 6029–6033.
56. Tong AW, Nemunaitis J (2008) Modulation of miRNA activity in human
cancer: a new paradigm for cancer gene therapy? Cancer Gene Therapy 15:
341–355.
57. Iguchi H, Kosaka N, Ochiya T (2010) Versatile Applications of microRNA in
Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers. Current Drug
Discovery Technologies 7: 95–105.
58. Iravani M, Dhat R, Price C (1997) Methylation of the multi tumor suppressor
gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic
leukemia. Oncogene 15: 2609–2614.
59. Hemmati PG, Mu ¨er A, Gillissen B, Overkamp T, Milojkovic A, et al. (2010)
Systematic genetic dissection of p14ARF-mediated mitochondrial cell death
signaling reveals a key role for p21CDKN1 and the BH3-only protein Puma/
bbc3. J Mol Med (Berl) 88(6): 609–22.
60. Mei M, Ren Y, Zhou X, Yuan XB, Han L, et al. (2010) Downregulation of miR-
21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol
Cancer Res Treat 9(1): 77–86.
61. Shu M, Zheng X, Wu S, Lu H, Leng T, et al. (2011) Targeting oncogenic miR-
335 inhibits growth and invasion of malignant astrocytoma cells. Mol Cancer 10:
59.
62. Stinson S, Lackner M, Adai A, Yu N, Kim HJ, et al. (2011) TRPS1 targeting by
miR-221/222 promotes the epithelial-to-mesenchymal transition in breast
cancer. Science Signaling 4: pt5.
63. William M, Merritt MD, Yvonne G, Lin MD, et al. (2008) Dicer, Drosha, and
Outcomes in Patients with Ovarian Cancer. N Engl J Med 359(25): 2641–50.
64. Grelier G, Voirin N, Ay AS, Cox DG, Chabaud S, et al. (2009) Prognostic value
of Dicer expression in human breast cancers and association with the
mesenchymal phenotype. British Journal of Cancer 101(4): 673–683.
65. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, et al. (2008) Dicer,
Drosha, and outcomes in patients with ovarian cancer. The New England
Journal of Medicine 359(25): 2641–2650.
miRNA Modeling
PLoS ONE | www.plosone.org 12 January 2012 | Volume 7 | Issue 1 | e3014066. Kumar MS, Pester RE, Chen CY, Lane K, Chin C, et al. (2009) Dicer1
functions as a haploinsufficient tumor suppressor. Gene & Development 23(23):
2700–2704.
67. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA
expression profiles classify human cancers. Nature 435(7043): 834–838.
68. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T (2007) Impaired microRNA
processing enhances cellular transformation and tumorigenesis. Nature Genetics
39(5): 673–677.
69. Moffat J, Sabatini DM (2006) Building mammalian signaling pathways with
RNAi screens. Nat Rev Mol Cell Biol 7: 177–187.
70. Behlke MA (2006) Progress towards in vivo use of siRNAs. Mol Ther 13:
644–670.
71. Chung CH, Bernard PS, Perou CM (2002) Molecular portraits and the family
tree of cancer. Nat Genet 32: 16–26.
72. Hoheisel JD (2006) Microarray technology: beyond transcript profiling and
genotype analysis. Nat Rev Genet 7: 200–210.
73. Okamura K, Liu N, Lai EC (2009) Distinct mechanisms for microRNA strand
selection by Drosophila Argonautes. Mol Cell 36: 431–44.
74. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev
Cancer 6: 857–66.
75. Petri CA (1962) Kommunikation mit Automaten (PhD Thesis), Institut fu ¨r
Instrumentelle Mathematik, Bonn, Germany.
76. Bernardinello L, de Cindio F (1992) A Survey of Basic Net Models and Modular
Net Classes. Springer Verlag, Berlin, Germany.
77. Murata T (1988) Petri Nets: Properties, Analysis and Applications. Proceedings
of The IEEE 77(4): 541–580.
78. Markoswski A, Markoswski P (1990) Conditions for the effectiveness of a
preliminary test of variance. The American Statistician 44(4): 322–326.
miRNA Modeling
PLoS ONE | www.plosone.org 13 January 2012 | Volume 7 | Issue 1 | e30140